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ABSTRACT 
 
TOTAL SYNTHESIS OF CLAVATADINE A ANALOGS TO PRODUCE A VIABLE 
REVERSIBLE INHIBITOR FOR FACTOR XIA 
by 
Christopher Eric Malmberg 
June 2015 
 Cardiovascular disease has quickly become a major health concern in the United 
States, with numerous citizens dying from cardiovascular disease each year. Older 
medications, while effective against cardiovascular disease, are problematic to prescribe. 
A recently isolated natural product, clavatadine A, selectively inhibits human blood 
coagulation factor XIa. As a result, the synthesis and biological testing of clavatadine A 
and synthetic clavatadine A analogues that selectively inhibit factor XIa would represent 
a new direction in cardiovascular disease research. A potent and selective factor XIa 
inhibitor has the potential to be a safer replacement for current anticoagulants, such as 
Warfarin, Pradaxa®, Eliquis®, and Xarelto®. The first total synthesis of clavatadine A was 
recently completed. Clavatadine A binds irreversibly to the active site of factor XIa; 
therefore, a primary goal of this research is to design an analogue of clavatadine A that is 
a selective, reversible factor XIa inhibitor. The general approach developed for the 
synthesis of guanidine containing natural products was used to attempt to prepare several 
synthetic analogues of clavatadine A. First, the original four analogues of clavatadine A 
that included a urea, reverse carbamate and two amide analogues were attempted in hopes 
iv 
 
to synthesize an analogue that was less likely to form a covalent bond with Ser-195 in the 
active site of factor XIa. Phase two analogues were also attempted when the orginal four 
analogues did not work out as planned. Phase two included attempting to make a five 
carbon clavatadine A. 
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CHAPTER I  
INTRODUCTION 
1.1: Cardiovascular Disease 
Cardiovascular disease has quickly become the leading cause of death for humans 
in the developed world, causing 23% of all deaths in the United States in 2011.1 
Cardiovascular disease is a broad term that encompasses many conditions that involve the 
heart, arteries, capillaries and veins. The most notorious manifestations of cardiovascular 
disease include ischemic stroke, myocardial infarction, pulmonary embolism (blood flow 
is obstructed within the lung), peripheral artery disease, and deep vein thrombosis.2  
These cardiovascular conditions can be caused when the body loses control of 
hemostasis, which is the process of controlling how blood coagulates and how 
coagulation is regulated.3 Unregulated coagulation can result in either the inhibition of 
clotting (leading to hemophilia), or hyperactivity of coagulation (leading to thrombosis). 
Thrombosis is a leading cause of cardiovascular disease manifestations, and is the main 
target in preventing cardiovascular diseases.4 When there is a hyperactivity of 
coagulation, a thrombus (blood clot) is usually made, which can become lodged in a 
blood vessel and obstruct blood flow. Some examples of a thrombus traveling and getting 
lodged in a blood vessel are ischemic strokes and myocardial infarction, which is when a 
thrombus is lodged in a blood vessel in the brain or heart, respectively. These conditions 
can also occur from sitting too long while traveling, having an inactive lifestyle, or just 
not being able to move extremities (paraplegia), and will most likely cause peripheral 
 
artery disease (the obstruction of large arteries in limbs) and deep vein thrombosis (the 
obstruction of veins in limbs).
For hemostasis to function properly it relies heavily on the blood coagulation 
pathway, which is made up of two pathways that involve serine proteases and protein
protein interactions to form fibrin, and 
ultimately form a thrombus to stop 
hemorrhaging (Figure 1-1).
pathway is the tissue-factor pathway 
(extrinsic), which is activated when 
factor VII is exposed to the extravascular 
membrane protein, tissue factor (TF), at an injury site, and forms a 
factor VIIa (FVIIa).2,6 Factor VIIa
forms a complex with factor Va to cleave prothrombin into thrombin.
activates more platelets and causes fibrin to form in order to stop hemorrhaging.
contact-activation pathway (intrinsic) functions in the same way as the tissue factor 
pathway, except that it is activated by factor XII coming in contact with a negatively 
charged surface and forming factor XIIa. Factor XIIa then goes on to activate factor XI 
XIa, which then activates factor IX to IXa. Once factor IXa is activated the two pathways 
begin to merge because IXa activates factor X to Xa, which leads to the formation of 
fibrin as in the tissue factor pathway.
blood to form a hemostatic plug or clot. For clotting to occur properly all of the serine 
2 
4 
5,6 The first 
complex that activates 
-TF complex then activates factor X to Xa that then 
6,7 Thrombin then 
6,7 Fibrin is a protein that works with platelets in the 
Figure 1-1: Coagulation cascade
-
5 The 
to 
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protease enzymes must function properly. If one serine protease does not function 
properly, then the whole pathway will not create fibrins, and clotting will not occur. If 
this situation is left untreated, coagulation disorders like hemophilia (excessive bleeding) 
or thrombosis (excessive clotting) can occur, with the latter being the main cause of 
cardiovascular conditions. 
1.2: Past and Present Treatments 
Cardiovascular disease can be managed with medication, but the commonly 
prescribed medications can cause more harm than good if not monitored carefully. The 
most commonly prescribed medications used to treat thrombosis-related conditions over 
the last sixty years are warfarin and heparin.8 Although warfarin and heparin are effective 
at blood thinning, the dose given to a patient must be carefully monitored because an 
overdose can easily result in excessive bleeding and other complications arising from 
interactions with other pharmaceutical drugs or food.8 Warfarin and heparin are not ideal 
cardiovascular disease medications because they are non-specific inhibitors and can 
interact with similar or even unrelated proteins and cause unwanted side effects. To 
eliminate the complications of the unwanted side effects, scientists and pharmaceutical 
companies have directed drug discovery efforts towards specific coagulation factors. 
New anticoagulation drugs have become available that specifically target 
coagulation pathway proteins, and seem to avoid some of the complications that plagued 
warfarin and heparin. Two of the new drugs on the market in 2012 and 2013 are 
rivaroxaban (Xarelto®, manufactured by Bayer) and apixiban (Eliquis®, manufactured by 
Bristol-Myers Squibb), which target and inhibit coagulation factor (FXa).4 Another drug 
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approved by the FDA for treatment of strokes was dabigatran etexilate (Pradaxa®, 
manufactured by Boehringer-Ingelheim), which targets and inhibits thrombin (FIIa).9 All 
of these anticoagulation drugs show an improvement over warfarin and heparin in terms 
of their therapeutic index (toxicity dose divided by effective dose) and they may prove to 
be safer for patients. 
However, these new medications still have some of the same drawbacks as 
warfarin and heparin, which when taken by a patient can cause substantial bleeding risk if 
trauma occurs.9,10 Even with an improved therapeutic index, doctors must monitor doses 
closely and administer antidotes to the anticoagulant medications if severe bleeding 
occurs.11 These new medications are more precise than old medications because they are 
targeting specific coagulation factors with fewer side effects. Unfortunately, these new 
medications are targeting coagulation factors that are essential to form clots. Therefore, 
once one of these coagulation factors has been inhibited, the coagulation pathway may 
cease to function, thus disrupting hemostasis and preventing clots from forming. These 
medications, while not perfect, do have ideal anticoagulant characteristics like 
reversibility and specificity, and show progress towards a treatment for thrombosis.12 
One way to treat thrombosis without the risk for excessive bleeding is to target a 
coagulation factor that is part of the amplification phase of a clot, and not the 
construction phase. Factor XIa is an interesting target because its structural features 
distinguish it from vitamin K-dependent proteases. Because it is being made up of four 
apple domains, it resembles α-kallikrein more than other blood coagulation proteases.13 
Studies have suggested that inhibiting factor XIa (FXIa) could treat thrombosis while 
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leaving the coagulation pathway intact and allowing clotting to occur.2,3,9,12 While other 
drugs have targeted different proteins in the coagulation pathway, factor XIa is a more 
suitable target because it has the potential to be inhibited without the disadvantage of 
disrupting the coagulation pathway.10 This is possible because factor XIa is part of the 
amplification phase of the intrinsic pathway, so once the pathway has been activated, 
factor XIa helps to increase the clot size. Developing a molecule that can inhibit factor 
XIa into a drug, and thus slowing down the rate at which clots grow is promising because 
studies on patients with factor XIa deficiency (hemophilia C) have shown that there 
might not be a high bleeding risk unless major trauma is involved.3 Therefore, a 
medication that is a specific inhibitor of factor XIa may also reduce complications and 
have a higher therapeutic ratio than any previous thrombosis medication.  
Recently, factor XIa has become a prime target to treat cardiovascular disease, 
with numerous new molecules being discovered and tested in the last few years. Most of 
these newly discovered molecules or analogues target the allosteric site of factor XIa in 
order to have a greater specificity to factor XIa over structurally-related serine proteases. 
This occurs by a molecule targeting a site on factor XIa that is not its active site, once the 
molecule binds to factor XIa it negatively inhibits the factor by altering the active site and 
not allowing it to bind to factor IX. One of those molecules is a derivative of 
tetrahydroquinoline a very potent inhibitor with a Ki value of 0.20 nM .
14 Unfortunately, 
this derivative is also potent kallikrein inhibitors, which can cause cardiovascular 
problems involving blood pressure and other problems related to kallikrein functions.14,15 
Another newly discovered molecule is hydroxyquinolin-2(1H)one, which has a Ki value 
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of 0.04 nM for factor XIa.16 Hydroxyquinolin-2(1H)one, however, suffers from the 
same drawbacks as the tetrahydroquinoline derivative, in that it is also a potent inhibitor 
of kallikrein.16 This complication could arise from the fact that factor XIa and α-
kallikrein are trypsin-like enzymes and come from the same chymotrypsin family of 
serine proteases.17 This complication can also affect active site binders if the designed 
molecule is not selective enough.17 
1.3: Clavatadine A and Analogues 
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A molecule that has shown the ability to inhibit factor XIa specifically is the 
recently isolated natural product clavatadine A.18 With an IC50 of 1.3 µM for factor XIa, 
clavatadine A offers promise as an anticoagulant medication.18 The Chamberland 
research group at Central Washington University was able to successfully synthesize 
clavatadine A for the first time in a laboratory using a streamlined approach (Figure 1-
2)19. This approach broke clavatadine A down into two manageable molecules; a 
dibromophenol (2) and a protected guanidine side chain (1)19. These pieces were then 
joined together by reacting an isocyanate with a dibromophenol to form the carbamate 
functional group that links the two pieces together to create a precursor of clavatadine 
(3)
19.Unfortunately, clavatadine A has one imperfection that keeps it from being an ideal 
anticoagulant, it is an irreversible binder to factor XIa.18 Clavatadine A is an irreversible 
inhibitor because 
when it enters the 
active site of factor 
XIa it binds with 
strong non-covalent 
interactions. Once 
Figure 1-3: Clavatadine A bound to factor XIa 
Figure 1-2: Clavatadine A synthesis 
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securely in the active site (Figure 1-3) , a nucleophilic alcohol of serine 195 from factor 
XIa attacks the carbamate of clavatadine A and forms an irreversible covalent bond.18 
This bond formation expels the aromatic portion and leaves the linear portion adhered to 
the active site. Bound to clavatadine A, factor 
XIa is rendered useless, which forces the body 
to destroy and remake the factor before it can 
be used to amplify clots. It is the goal of the 
Chamberland research group to extend the 
success of synthesizing clavatadine A by 
developing four first generation analogues of 
clavatadine A for a new medicinal chemistry 
program. These analogues are designed to be 
reversible inhibitors of factor XIa by having a less-labile group that interacts with serine 
195 but prevents cleaving of the molecule (Figure 1-4). This hypothesis will be tested by 
replacing the carbamate of clavatadine A with less-labile functional groups like an amide 
(7, 8), urea (6), or reverse carbamate (5). These new functional groups if successful will 
cause serine 195 to form a strong electrostatic interaction with the electrophilic carbonyl 
carbon of the functional groups, but should 
prevent cleavage of the molecule.  
Since these analogues are so similar to clavatadine A, routes that are similar to the 
synthetic route to make clavatadine A will be used to produce the analogues, but with 
slight modifications for the new molecules. As in the clavatadine A synthesis, each 
 
Figure 1-4: Original four analogues 
9 
 
analogue will be broken into two pieces, a dibromolactone portion and a protected 
guanidine side chain. Three of the analogues will start with the nitration of 2-
coumaranone, which will then go through a nitro reduction to produce an aniline that will 
then be brominated to produce the needed dibromoaniline. The linear guanidine side 
chain will be produced in the identical manner for the urea, and for one of the amide 
analogues. The reverse carbamate linear guanidine chain will start by protecting a 2-
methyl-2-thiopseudourea sulfate, and then reacting it with the necessary side chain. 
While planning for these first four analogues many other analogues that could be easily 
obtained by using the same subunits as the original four along with subunits form 
clavatadine A. These other analogues include clavatadine A and the orginal analogues, 
but with a five-carbon chains instead of a four-carbon chains, also replacing the 
carbamate or urea with a thiocarbamate or thiourea functional group. Adding an extra 
carbon could move the carbamate far enough away from serine 195 that it cannot 
covalently bond, while the sulfur atom is less electronegative and may make the carbonyl 
carbon less of a target for attack from the nucleophilic oxygen of serine 195. Once 
enough of each of these analogues is made they will then be tested using in vitro enzyme 
assays to determine their affinity for factor XIa and other enzymes, and to see if they are 
reversible and strong inhibitors.  
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Chapter II 
 SYNTHESIZING THE SUBUNITS 
2.1: Designing the analogues 
The original compounds that were chosen for synthesis were a urea, reverse 
carbamate, and amide analogues of clavatadine A. These four analogues were chosen in 
an attempt to make the carbamate functional group in clavatadine A less labile, making it 
less prone to attack from the hydroxyl group of serine 195 in factor XIa. While working 
towards the original analogues, several more easily obtainable analogues were planned 
using the same or similar subunits that would create the first four analogues, or by 
modifying the carbamate by replacing the carbonyl oxygen with a less electronegative 
atom.  
To make all of these analogues, the same convergent scheme that included an 
early guanidinylation method that created clavatadine A was used.1 This involved 
breaking the molecule down into two subunits, a lactone subunit and a linear, guanidine 
containing subunit. These two subunits would later be joined together using an isocyanate 
to form a carbamate. Each analogue like clavatadine A was broken down into its lactone 
and linear, guanidine containing subunits by breaking the carbonyl containing functional 
group in the middle of the molecules. This left many new subunits that needed to be 
synthesized, along with subunits that could be reused from the clavatadine A synthesis. 
These subunits may later be joined together using an isocyanate or chloroformate 
functional group. 
12 
 
 
2.2: Creating the Lactones 
 Retrosynthetic analysis showed that the target analogues could be synthesized by 
using only two different lactone subunits. The first lactone subunit that was synthesized 
was 4,6-dibromohomogentisic acid lactone, which is the same lactone subunit that was 
used to create clavatadine A.1  This first lactone subunit was synthesized by first taking 
2,5-(dimethoxyphenyl)acetic acid (9) and treating it with HBr to give homogentisic acid 
lactone (Figure 2-1).1 
Figure 2-1: Synthesis of homogentisic acid lactone (10) 
O
O
HOOH
O
OMe
MeO
HBr (aq)
96%
9 10
13 
 
 With o-hydroxyphenylacetic acid in its lactone form the highly reactive and polar 
molecule can undergo further reactions and purification without fear of unwanted side 
reactions taking place. The crude product of this reaction was then purified using 
decolorizing carbon and recrystallization, to obtain a low yield of product. It was then 
found that these steps could be eliminated to give a pure product with a yield of 96% to 
97%, when a 1H NMR spectrum was taken of the crude product before recrystallization 
in an attempt to discover why the reaction produced a low yield. The homogentisic acid 
lactone (10) was then brominated using Br2 and NaOAc in acetic acid, to obtain 4,6-
dibromohomogentisic acid lactone (2) at a yield of 68%.1 Both bromines add ortho to the 
hydroxy group because it is an ortho, para director (figure 2-2). The first bromine adds to 
C-6 of the ring because that site is less sterically hindred.  
Figure 2-2: Synthesis of dibrominated homogentisic acid lactone (2) 
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 To synthesize the next lactone subunit a different method had to be employed 
because the hydroxy group needed to be replaced with an amino group. Retrosynthetic 
analysis showed that to synthesize the dibrominated aniline that was needed for 
analogues 5-7, it was more cost effective and efficient to start with 2-coumaranone (11). 
2-Coumaranone (11) was subjected to a simple nitration reaction by dissolving it in acetic 
acid and adding it to a solution of HNO3 and H2SO4 (Figure 2-3).
2 This reaction provided 
a yield of 50% or less at first, until the reaction was split up into multiple flasks and 
allowed to stir for a longer amount of time, which provided a yield of 70%. This nitro 
O
O
O
O
O2N
Acetic Acid
70%
11 12
H2SO4, HNO3
Figure 2-3: Synthesis of nitro coumaranone 
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coumaranone (12) was subjected to a reduction reaction using hydrogen gas and a 
palladium on carbon catalyst to reduce the nitro group to an amino group (Figure 2-4). 
This reaction was successful while working with small quantities, providing a yield of 
99%. When tried on a large scale however, over 400 mg, the reaction would take longer 
and could lead to dimerization of the newly formed amino coumaranone (13) with 
another amino coumaraone (13) or nitro coumaraone (12). This occurs because esters or 
lactones are extremely susceptible to attacks from amines, when in contact with one 
anonther these molecules can go through an aminoylsis reaction. The amino 
coumaranone (13) was then brominated by dissolving it in ethyl acetate and adding Br2 
(Figure 2-5).  
Figure 2-5: Forming the dibrominated amino coumaranone 
 This reaction provided a yield of 40% dibrominated amino coumaranone (14), with the 
monobrominated amino coumaranone as the major product. With the two lactones 
successfully synthesized it was time to synthesize the many linear, guanidine containing 
subunits. 
Figure 2-4: Forming amino coumaranone 
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2.3: Linear guanidine containing subunits 
 Retrosynthetic analysis showed that four different linear, guanidine containing 
subunits needed to be synthesized to complete all the desired analogues. One of the four 
linear chains included the same linear subunit that was used to make clavatadine A. 
Another contained a linear chain with one extra CH2 resulting in a five carbon chain 
instead of a four carbon chain. First all the linear, guanidine containing subunits were 
synthesized by starting with an N,N-di-Boc guanidine (16). To synthesize N,N-di-
Boc guanidine (16) a solution of guanidine hydrochloride (15) dissolved in 1,4 dioxane 
was treated with di-tert-butyl dicarbonate and sodium hydroxide, providing a yield of 
56% (figure 2-6).3 
Figure 2-6: Forming N,N-di-Boc guanidine (16) 
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 The N,N-di-Boc guanidine (16) was then dissolved in dichloromethane, and treated 
with triflic anhydride under anhydrous and high dilution conditions to produce N,N-di-
Boc-N-triflylguanidine (17), or better known as a Goodman’s reagent at a 46% yield 
(Figure 2-7).3 N,N-di-Boc-N-triflylguanidine (17) was then reacted with 1,4-
butanediamine (18) by using a modified version of the procedure that Botta et al. and 
Munoz et al. developed.4,5 This lead to the first linear, guanidine containing subunit (19) 
that was needed for the analogues (Figure 2-8).4 To create the linear, guanidine 
containing subunit that has a five carbon chain (21), the exact same method was 
employed, except the Goodman’s reagent was reacted with 1,5-pentanediamine (20) 
(Figure 2-9).4  
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17
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Figure 2-7: Synthesis of Goodman’s reagent (17) 
Figure 2-8: Synthesis of the four carbon linear chain 
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Figure 2-9: Synthesis of five carbon linear chain 
 The last two linear, guanidine containing subunits that needed to be synthesized 
all had a terminal hydroxyl group on the end of the carbon chain instead of an amine. Due 
to the potential of the same method not working, a new method to create the hydroxy 
linear, guanidine containing subunits was employed. This new method started out with 2-
methyl-2-thiopseudourea (22) being treated with di-tert-butyl dicarbonate and sodium 
bicarbonate to give 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (23) with a 
yield of 82% (Figure 2-10).6,7 This compound was then refluxed with either 4-amino-1-
butanol or 5-amino-1-pentanol (24) to give the desired linear, guanidine containing 
subunits (25) with a terminal hydroxy group (Figure 2-11).8 The reaction with 4-amino-1-
butanol was not attempted because of the cost and amount of 4-amino-1-butanol, which 
was only going to be attempted if the synthesis of the reverse carbamate analogue with 
the five carbon chain was successful. Later on in the synthesis of the clavatadine A 
analogues the method used to create linear, guanidine containing subunits with terminal 
amines was tested using 5-amino-1-pentanol (24) to see if the reaction was capable of 
Figure 2-10: Forming 1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea 
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Figure 2-11: Synthesis of five carbon hydroxyl linear chain (25) 
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creating all four analogues.4 The reaction was successful, so only the Goodman’s reagent 
method was later employed. 
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Chapter III 
ATTEMPTING THE ANALOGUES 
3.1:  Urea Analogue 
 Once all the subunits were successfully synthesized it was time to start joining 
them together to create analogue precursors. As in the synthesis of clavatadine A, the two 
subunits were connected by converting the terminal amine of the linear, guanidine 
containing subunit (19) into a highly reactive and electrophilic isocyanate (26) and then 
reacting that with a dibrominated lactone (2) that acted as a nucleophile. The analogue 
subunits would be connected following the same method, by either using an isocyanate of 
chloroformate functional group. 
 Initially the first analogue that was attempted was the urea analogue (25) , and 
this involved converting the amine on the linear guanidine containing chain (19) to an 
isocyanate group using triphosgene (Figure 3-1).1 Once the isocyanate (26) was 
confirmed an FTIR peak at 2265 cm-1, it was then dissolved in dichloromethane and a 
catalytic amount of Hünig’s base added to it, before dibrominated amino coumaranone 
(in DCM) was added dropwise (Figure 3-2).2–4 This solution was then allowed to stir for 
thirty minutes. TLC did show new spots, so the crude product was tested using 1H NMR 
spectroscopy for the appearance of two N-H peaks signaling that a urea functional group 
Figure 3-1: Synthesis of the isocyanate 
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was formed between the two subunits. The NMR analysis revealed no evidence of this 
occurring. The same reaction was repeated to see if any of the urea analogue could be 
22 
 
formed using this method, but still no evidence of the urea analogue forming. It was then 
decided to attempt the same reaction, but with the isocyanate on the dibrominated amino 
23 
 
coumaranone (28) instead of the linear chain to see if the urea analogue could be formed. 
To do this, the dibrominated amino coumaranone (14) was dissolved in ethyl acetate, 
treated with triphosgene, and allowed to reflux for five hours (Figure 3-3).5,6 Again, FTIR 
confirmed an isocyanate peak, at 2274 cm-1. The isocyanate was then dissolved in 
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dichloromethane and a catalytic amount of base added to it before the linear chain (19) 
was added dropwise (Figure 3-5).2,3 This new method also showed no evidence of the 
urea analogue being formed. It was then hypothesized that one of the amines in the 
reaction was acting as a base and that adding a catalytic amount of base to the reaction 
could be killing the chemistry, because the solution would become too basic. This 
method was tried with the isocyanate group on the dibrominated aniline, but showed no 
evidence of a urea functional group either. 
3.2: Reverse Carbamate 
The next analogue attempted was the reverse carbamate (5) (Figure 3-6), which 
used the method where the isocyanate was on dibrominated amino coumaranone, since 
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Figure 3-3: Synthesis of amino coumaranone isocyanate 
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Figure 3-4: Synthesis of the urea analogue (27) scheme 2 
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the linear chain had a terminal alcohol (25) and therefore could not form an isocyanate 
group. Using the same method as the urea analogue, an isocyanate group was formed on 
the dibrominated amino coumaranone (28), which was then reacted with the hydroxy 
linear chain (Figure 3-5).4–6 An 1H NMR spectrum did not contain an N-H peak, 
suggesting that the carbamate had not formed. This reaction was then repeated multiple 
times, with no evidence of the carbamate forming. A new method was then devised that 
used a chloroformate functional group instead of an isocyanate. Using a chloroformate 
allowed the highly reactive functional group to be on placed on the primary hydroxy 
group of the linear chain, as in the clavatadine A synthesis. It was hypothesized that 
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having an isocyanate on the dibrominated amino coumaranone (27) made the isocyanate 
less likely to react due to steric hindrance of the bromines or possible electrical 
interference from the coumaranone. This method was then tested by reacting the linear 
chain with a terminal hydroxy group with triphosgene to form a chloroformate (30) 
(Figure 3-6).7,8 1H NMR and FTIR spectroscopy confirmed that the chloroformate (30) 
had been formed; therefore it was quickly dissolved in dichloromethane and had a 
catalytic amount of base added to it before dibrominated amino coumaranone (14) was 
added dropwise (Figure 3-7).9 This reaction also produced no evidence of the carbamate 
forming.  
Figure 3-5: Synthesis of the reverse carbamate (29) scheme 1 
Figure 3-6: Synthesis of chloroformate (30) 
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3.3: Testing the Chemistry 
28 
 
Since none of these reactions formed the desired product, a series of test reactions 
was designed and performed to determine if there was something wrong with the 
chemistry of the reactions, or if other errors occurred. The first series of reactions used 
two compounds that were already in the lab that could form a carbamate and that were 
similar to the subunits of the analogues, specifically benzyl chloroformate (32) and p-
toluidine (31). First, p-toluidine was dissolved in tetrahydrofuran and a catalytic amount 
of imidazole was added to the solution. Then, the benzyl chloroformate was added 
dropwise, and this reaction was left to stir over night (Figure 3-8).10 This reaction did 
show evidence of a carbamate forming, with an N-H peak at 6.72 ppm, that matched 
Figure 3-7: Synthesis of reverse carbamate (29) scheme 2 
Figure 3-8: Test reaction to form carbamate 
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reported spectra of the compound.10 The next test reaction involved reacting the 
dibrominated amino coumaranone (14) with benzyl chloroformate (32) using identical 
conditions to see if there was something wrong with the chemistry, since user error had 
been ruled out when the test reaction formed a carbamate. Following the same method as 
the first test reaction the second test reaction was performed, with no evidence of a 
carbamate being formed. This reaction was then performed multiple times using a 
variation of stronger and weaker bases, with still no evidence of a carbamate being 
formed. The next test reaction involved reacting the amino coumaranone (13) with benzyl 
chloroformate (32) to see if the bromines were sterically hindering the reaction to 
combine the two subunits. Using the same conditions as the first test reaction benzyl 
chloroformate (32) and amino coumaranone (13) were reacted together. The 1H NMR 
spectrum of the crude product of the reaction showed promise, with some evidence of 
carbamate N-H peaks from a formed carbamate. Another test reaction on a larger scale 
will have to be conducted before the actual chloroformate subunit is used on amino 
coumaranone. 
 After running several different test reactions it was hypothesized that the 
bromines on the ring of the dibrominated coumaranone coupled with the amine was 
causing some form of 1,3-allylic strain that hindered the carbamate forming reactions. 
Usually allylic strain is seen when substituents the size of methyl groups get to close to 
each other, in this case it is most likely due to the hydrogens of the amine and the 
bromines being too close to each other. To avoid strain as much as a possible the 
molecule likely has the lone pair of the amine in the plane of the ring directed at one of 
30 
 
the bromines, while the hydrogens are on opposite sides of the ring flanking the other 
bromine. This conformation leaves the lone pair of the amine hindered and unable to 
attack the carbonyl carbon of an isocyanate or chloroformate functional group. This 
hypothesis is supported by the fact that the alcohol on the dibrominated homogentisic 
acid lactone readily reacts with an isocyanate. This is because dibrominated homogentisic 
acid lactone in any conformation will always have a lone pair that is unhindered and 
accessible.  
3.4: Five Carbon Clavatadine A 
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 The last analogue that was attempted was the five carbon linear chain clavatadine 
A (35), this molecule is exactly the same as clavatadine A except it has one extra carbon 
on its linear, guanidine containing subunit. This analogue is a desired target because the 
one extra carbon on the linear chain could move the carbonyl carbon of the carbamate far 
enough away from serine 195 of factor XIa to keep it from binding covalently. To make 
this analogue the same synthesis route to make clavatadine A was used, except that 1,5-
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diaminobutane was used to make the linear subunit (21).4 As in the synthesis of 
clavatadine A the reaction between the isocyanate and the lactone (Figure 3-9) was 
almost immediate, and a strong spot not correlating to starting material appeared by TLC 
after fifteen minutes.  The crude 1H NMR spectrum showed an extra peak at 7.24 ppm, 
which was originally thought to be the N-H peak, but after purifying the material by 
column 
chromatography the real N-H peak appeared at 5.33 ppm as a broad triplet. The precursor 
to the extra carbon clavatadine A (34) had been made successfully, and then just need to 
bwreacted with HCl to open up the lactone and deprotect the guanidine to give the first 
completed analogue.  
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APPENDIXES 
APPENDIX A 
Experimental/Suppleamental data 
 
 All solvents and reactants that were used were purchased from Sigma-Aldrich 
Chemical Supply Company, VWR Chemical Supply Company, or the ACROS Chemical 
Supply company. Nitrogen gas used to produce an inert atmosphere, and hydrogen gas to 
produce a hydrogen atmosphere were provided by the Central Washington University 
Chemistry department and was purchased from OXARC. All flash column 
chromatography used EMD silica gel 60, 230-400 mesh. 
 
Di-Boc guanidine
1
 21:  To a solution of 1,5-pentanediamine (20) (0.385 mL, 3.269 
mmol, 3.0 equiv) in 5 mL of CH2Cl2 was added Et3N (0.151 mL, 1.09 mmol, 1.0 equiv). 
Then, a solution of N,N-di-Boc-N-triflylguanidine (17) (Goodman’s reagent) (426.7 
mg, 1.09 mmol, 1.0 equiv) in 5 mL of CH2Cl2 was added dropwise by addition funnel 
over 1 h (the reaction mixture grew cloudy), and the reaction mixture was stirred at 
ambient temperature for 12 h. Goodman’s reagent was prepared following the procedure 
published by Goodman et al.2 After 12 h, the reaction mixture was gravity filtered to 
remove suspended solids, and then was washed with saturated aqueous NaHCO3 (2 × 3 
mL), H2O (2 × 3 mL), and brine (1 × 3 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. Purification by flash column chromatography on silica gel (5:3:2 
EtOAc/MeOH/Et3N) afforded the product as a white powder (333.4 mg, 89%):  Rf = 
35 
 
0.36, 5:3:2 EtOAc/MeOH/Et3N; 
1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 1H), 8.31 (br 
s, 1H), 3.42 (dt, J = 7.2, 5.2, 2H), 2.70 (dt, J = 7.2, 6.8, 2H), 1.59 (quint, J = 7.2, 2H)  
1.52–1.47 (m, 2H), 1.51 (s, 9H), 1.50 (s, 9H), 1.42–1.36 (m, 2H); 13C NMR (CDCl3, 100 
MHz) δ 163.7, 156.1, 153.4, 83.0, 79.2, 42.0, 40.8, 33.4, 28.9, 28.3, 28.1, 24.2;  
 
Di-Boc guanidine
1
 19:  To a solution of 1,4-butanediamine (18) (3.10 mL, 26.4 mmol, 
3.0 equiv) in 365 mL of CH2Cl2 was added Et3N (1.22 mL, 8.78 mmol, 1.0 equiv). Then, 
a solution of N,N’-di-Boc-N”-triflylguanidine2 (3.436 g, 8.78 mmol, 1.0 equiv) in 15 mL 
of CH2Cl2 was added dropwise by addition funnel over 1 h (the reaction mixture grew 
cloudy), and the reaction mixture was stirred at ambient temperature for 12 h. After 12 h, 
the reaction mixture was gravity filtered to remove suspended solids, and then was 
washed with saturated aqueous NaHCO3 (2 × 50 mL), H2O (2 × 50 mL), and brine (1 ×50 
mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification by 
flash column chromatography on silica gel (5:3:2 EtOAc/MeOH/Et3N) afforded the 
product as a pale yellow oil (2.663 g, 98%): Rf = 0.39, 5:3:2 EtOAc/MeOH/Et3N; 
1H 
NMR (CDCl3, 400 MHz) δ 11.50 (br s,1H), 8.35 (br s, 1H), 3.43 (td, J = 7.2, 4.8, 2H) 
2.74 (t, J = 7.0, 2H), 1.63 (m, 2H), 1.53 (m, 2H), 1.51 (s, 9H), 1.49 (s, 9H); 13C NMR 
(CDCl3, 100 MHz) δ 163.6, 156.2, 153.3, 83.1, 79.3, 41.8, 40.7, 30.8, 28.3, 28.1, 26.4 
 
Linear chain isocyanate
1,3
 26: To a 25 mL round-bottom flask was added 20 mg of 
amine (19) (20 mg, 0.0581 mmol, and 1 equiv), 1 mL of CH2Cl2,. This solution was then 
cooled to 0 ºC using an ice-water bath, and then the solution was then charged with 6.8 
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mg of triphosgene (6.8 mg, 0.0232 mmol, and 0.4 equiv). To this solution was added 1 
mL of saturated NaHCO3, and the mixture was left to stir for 30 min at 0 ºC. The solution 
was then diluted with 3 mL of CH2Cl2 and 3 mL H2O. The organic layer was removed 
and the aqueous layer was extracted with 2 × 3 ml CH2Cl2. The combined organic layers 
were washed with 10 mL of H2O and 10 mL of brine, and over anhydrous Na2SO4, 
filtered and concentrated in vacuo to give 22.5 mg (107%) of white powder:   
 
Nitro-Coumaranone
4
 12:  To a 25 mL round-bottomed flask was added concentrated 
nitric acid(0.697 mL, 15.5 mmol, 4.16 equiv) and concentrated sulfuric acid (0.663 mL, 
12.45 mmol, 3.34 equiv). This solution was then cooled to 5 °C using an ice-water bath. 
Then, a solution of 2-coumaranone (11) (0.500 g, 3.727 mmol, 1.0 equiv)  in 0.860 mL of 
acetic acid was added dropwise to the cooled acid solution. Yellow crystals appeared 
immediately. This solution was the left to stir for 20 minutes at 5 °C. After stirring, ice 
and water were added to the mixture. The resulting yellow powder were then filtered and 
washed with methyl tert-butyl ether, and left to dry. The dry yellow powder weighed 
0.4085g (61% yield):  1H NMR (DMSO-d6, 400 MHz) δ 8.27 (dd, J = 11.8, 2H), 7.43 (d, 
1H), 4.04 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ 173.42, 158.76, 143.59, 126.42, 
125.02, 120.53, 110.76, 32.76 
 
Amino Coumaranone 13:  To a flame-dried 25 mL round-bottom flask under an N2 
atmosphere was added 50 mg of nitro-coumaranone (12) (50 mg, 0.277 mmol, and 1.0 
equiv) and 8 mL of EtOAc. This solution was then charged with a spatula-tip full of 10% 
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palladium on carbon catalyst. The flask was then flushed with H2 gas, and left with a 
balloon of H2 gas while the solution stirred for 2 h or until starting material disappeared 
from TLC. The palladium was then filtered off and the resulting solution was 
concentrated in vacuo. The dry white powder weighed 40.8 mg (98% yield): 1H NMR 
(DMSO, 400 MHz)  6.83 ( d, J = 8.4,1H), 6.55 ( s, 1H), 6.46 (dd, J =6.2, 2H), 4.93 (br 
s, 2H), 3.78 (s, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 175.0, 145.34, 144.94, 124.43, 
112.63, 110.17, 110.07, 33.06 
 
Dibromoaniline
5
 14:  To a flame dried 25 mL round-bottomed flask under an N2 
atmosphere was added 50 mg of amino coumaranone (13) (50 mg, 0.333 mmol, and 1.0 
equiv) and 8 mL of ethyl acetate. This solution was then cooled to -78 ºC. The flask was 
then charged with Br2 (0.0513 mL, 0.990 mmol, 3.0 equiv). This solution was then 
allowed to stir for 6 hours and the disappearance of starting material: 1H NMR (DMSO-
d6, 400 MHz) δ 7.41 (s, 1H), 5.16 (br s, 2H), 3.82 (s, 2H); 
13C NMR (CDCl3, 100 MHz) δ 
172.07, 145.81, 138.94, 124.81, 114.0, 107.38, 104.91, 35.20 
 
Aniline isocyanate
6,7
27: To a 25 mL round-bottomed flask was added 100 mg of 
dibrominated aniline (14) (100 mg, 0.3258 mmol, 1 equiv), 4 mL of CH2Cl2, and 4.5 µL 
of triethylamine. This solution was then cooled to 0 ºC using an ice-water bath, the 
solution was then charged with 96.7 mg of triphosgene (96.7 mg, 0.3258 mmol, 1 equiv). 
This solution was left to stir for 30 min at 0 ºC, then 1 h at room temperature. The 
solution was then heated at reflux for 5 h. Then the solution was allowed to cool to room 
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temperature, and then diluted with 3 mL ethyl acetate and 3 mL H2O. The organic layer 
was removed and the aqueous layer was extracted with 2 × 3 ml CH2Cl2. The combined 
organic layers were washed with 10 mL H2O and 10 mL brine, and dried over anhydrous 
Na2SO4 filtered and concentrated in vacuo to give 86.8 mg (79%) of orange powder:   
 
N,N-Bis(tert-butoxycarbonyl)-S-methyl-isothiourea
8,9
 (23):  To a clean 25 mL 
round-bottomed flask was added 2-methyl-2-thiopseudourea (100 mg, 0.719 mmol, 1.0 
equiv) and was then dissolved in 1.5 mL of CH2Cl2. To this solution was added 627 mg 
di-tert-butyl dicarbonate  (627 mg, 2.876 mmol, and 4.0 equiv) and 1.44 mL of NaHCO3. 
This solution was then left to stir for 18 hours. The layers were separated, and the 
aqueous phase extracted with CH2Cl2. The resulting organic solution was dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The product was then purified 
using column chromatography (1:3 EtOAc/Et2O). The resulting white powder weighed 
95.1 mg (82% yield):  1H NMR (CDCl3, 400 MHz) δ 11.61 (br s, 1H), 2.40 (br s, 1H), 
1.52 (s, 9H), 1.51 (s, 9H),  
 
N,N-Bis(tert-butoxycarbonyl)-N-(4-hydroxypentyl)guanidine (25)8,9: To a clean 
25 mL round-bottomed flask was added N,N-bis(tert-butoxycarbonyl)-S-methyl-
isothiourea (95.1 mg, 0.327 mmol, 1.0 equiv) and 67 mg of 5-amino-1-butanol (67 mg, 
0.654 mmol, 2.0 equiv) in 3 mL of THF. This solution was then heated at 50 °C for 2 h, 
and allowed to cool to room temperature. The solution was then diluted with 3 mL of 
CH2Cl2 and 3 mL of H2O. The organic layer was removed and the aqueous layer was 
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extracted with 2 × 3 ml of CH2Cl2. The combined organic layers were washed with 10 
mL of H2O and 10 mL of brine, and dried over Na2SO4, filtered, and concentrated in 
vacuo to give 92.7 mg (94%) of white solid: 1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 
1H), 8.32 (br s, 1H), 3.66 (t, J = 6.4, 2H), 3.42 (dd, J = 5.6, 6.8, 2H), 1.59 (quint, J = 7.2, 
2H)  1.52–1.47 (m, 2H), 1.51 (s, 9H), 1.50 (s, 9H), 1.42–1.36 (m, 2H); 13C NMR (CDCl3, 
100 MHz) δ 163.60, 156.17, 153.34,83.08, 79.29, 62.60, 40.78, 32.29, 28.86, 28.31, 
28.09, 23.05 
 
Chloroformate
10,11
 30:  To a clean, dry 25 mL round-bottomed flask was added N,N-
bis(tert-butoxycarbonyl)-N-(4-hydroxypentyl)guanidine (30 mg, 0.0868 mmol, 1.0 
equiv) and 2 mL of CH2Cl2. To this solution was added 6.87 mg of pyridine (7 µL, 
0.0868 mmol, 1.0 equiv), and it was cooled to 0 °C using an ice-water bath. Once cooled, 
triphosgene (7.731 mg, 0.026 mmol, 0.3 equiv) was added to the solution, and it was then 
left to stir for 4 hours. The solution was then diluted with 3 mL of CH2Cl2 and 3 mL of 
H2O. The organic layer was removed and the aqueous layer was extracted with 2 × 3 ml 
CH2Cl2. The combined organic layers were washed with 10 mL of H2O and 10 mL of 
brine, and dried over Na2SO4, filtered, and concentrated to give 24.5 mg (70%) of a 
transparent syrup. 1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 1H), 8.36 (br s, 1H), 4.33 (t, 
J = 6.4, 2H) 3.44 (dd, J = 5.6, 6.8, 2H) 1.77 (quint, J = 7.2, 2H)  1.62 (quint, J = 7.6 2H), 
1.50 (s, 18H) 
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5 Carbon Clavatadine A precursor
1
 33:  To a clean dry 25 mL round-bottomed flask 
was added 30 mg dibrominated homogentisic acid lactone (2) (41.6 mg, 0.1351 mmol, 
1.0 equiv), 1 mL of CH2Cl2, and Hünig’s base (4.61 µL, 0.02702 mmol, 0.2 equiv). To 
this solution was added linear chain isocyanate (35) (50 mg, 0.1351 mmol, 1.0 equiv), 
and was then left to stir for 1 h. The solution was then diluted with 3 mL of CH2Cl2 and 3 
mL of H2O. The organic layer was removed and the aqueous layer was extracted with 2 × 
3 ml of CH2Cl2. The combined organic layers were washed with 10 mL of H2O and 10 
mL of brine, and dried over Na2SO4, filtered, and concentrated to give 35.4 mg (70%) of 
a wet purple powder. Purification by flash column chromatography on silica gel afforded 
the product as a purple powder: 1H NMR (CDCl3, 400 MHz) δ 11.50( br s, 1H), 8.325 (br 
s, 1H), 7.322 (s, 1H), 5.328 (t, J = 5.76, 1H), 3.69 (s, 2H), 3.48 (dd, J = 6.8, 7.2, 2H), 
3.44 (m, 2H), 3.32 (dd, J = 6.4, 6.8 ,2H) 1.62 (m, 4H), 1.50 (s, 18H); 13C NMR (CDCl3, 
100 MHz) δ 171.35, 163.59, 156.20, 153.36, 152.14, 151.68, 142.61, 125.22, 118.24, 
115.01, 114.35, 83.16, 79.34, 41.25, 40.53, 34.72, 29.26, 28.60, 23.69 
 
N,N-Bis(tert-butoxycarbonyl)-N-(4-hydroxypentyl)guanidine
1
 (25):  To a solution 
of 5-amino-1-butanol  (0.337 g, 3.269 mmol, 3.0 equiv) in 5 mL of CH2Cl2 was added 
Et3N (0.151 mL, 1.09 mmol, 1.0 equiv). Then, a solution of N,N-di-Boc-N-
triflylguanidine (17) (Goodman’s reagent) (426.7 mg, 1.09 mmol, 1.0 equiv) in 5 mL of 
CH2Cl2 was added dropwise by addition funnel over 1 h (the reaction mixture grew 
cloudy), and the reaction mixture was stirred at ambient temperature for 12 h. Goodman’s 
reagent was prepared following the procedure published by Goodman et al.2 After 12 h, 
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the reaction mixture was gravity filtered to remove suspended solids, and then was 
washed with saturated aqueous NaHCO3 (2 × 3 mL), H2O (2 × 3 mL), and brine (1 × 3 
mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo, this afforded the 
product as a white powder (369.3 mg, 98%):1H NMR (CDCl3, 400 MHz) δ 11.50 (br s, 
1H), 8.32 (br s, 1H), 3.66 (t, J = 6.4, 2H), 3.42 (dd, J = 5.6, 6.8, 2H), 1.59 (quint, J = 7.2, 
2H)  1.52–1.47 (m, 2H), 1.51 (s, 9H), 1.50 (s, 9H), 1.42–1.36 (m, 2H); 13C NMR (CDCl3, 
100 MHz) δ 163.60, 156.17, 153.34,83.08, 79.29, 62.60, 40.78, 32.29, 28.86, 28.31, 
28.09, 23.05 
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APPENDIX B 
Spectroscopic Data 
All NMR spectroscopic data was collected using a Bruker Avance 400 
spectrometer at 400 MHz for 1H NMR and at 100MHz for 13C NMR. All infrared 
spectroscopy spectral data was collected using a Bruker Alpha, with a universal sample 
module with polished sodium chloride plates, or by using the platinum ATR module. 
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